ObesityNCT07097974
Evaluation of the Efficacy of the Composite WM Formula in Body Weight Change
A study testing WM formula liquid drink in people with Obesity, run by TCI Co., Ltd. at 1 site in Taiwan.
Trial summary
This study aims to evaluate the effects of the combined formula WM Formula, used as a dietary supplement, with a focus on improvements in glycemic and lipid parameters, body composition, and gut microbiota profiles. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Obesity
- What is being tested?
- WM formula liquid drink
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 0 participants
- Where
- 1 siteTaiwan
- Study dates
- 30 Aug 2025to 30 Dec 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Adults aged 18 years or older who are willing to sign the informed consent form.
- Body fat percentage: ≥30% for females and ≥25% for males.
- Non-pregnant and non-lactating women who agree to use physical contraceptive methods (e.g., condoms, intrauterine devices) throughout the study period.
Who cannot join
- Use of GLP-1 receptor agonists approved in Taiwan (e.g., liraglutide, semaglutide, dulaglutide), blood glucose-regulating medications, weight loss-related drugs or functional foods, probiotics, or gastrointestinal health-related supplements or medications within 30 days prior to the start of the study.
- History of chronic gastrointestinal disorders, seizure disorders or epilepsy, hepatic or renal diseases, malignancies, endocrine disorders, psychiatric illnesses, alcohol or drug abuse, or other major organic diseases based on medical history.
- History of gastrointestinal surgery, organ transplantation, or other major surgeries.
- History of hypoglycemia.
- Known lactose intolerance.
- Chronic diarrhea.
Show all 9Show fewer
- Acute gastroenteritis within 2 weeks prior to study initiation.
- Known allergy to any ingredient in the investigational product.
- Employees or immediate family members of TCI Co., Ltd.
Trial locations and contacts
1 site in 1 country.
About this study
This study aims to evaluate the effects of the combined formula WM Formula, used as a dietary supplement, with a focus on improvements in glycemic and lipid parameters, body composition, and gut microbiota profiles.
Read the detailed description
This study is a single-center, randomized, double-blind, placebo-controlled human clinical trial designed to evaluate the potential effect of the WM Formula composite supplement on body weight. Eligible participants will be adults aged 18 years or older, screened based on waist circumference or body fat percentage.
Participants will be randomly assigned to one of two groups: one receiving the combined formula WM Formula, and the other receiving a placebo. Each group will take either the WM Formula or placebo, and undergo regular assessments throughout the 4-week study period. Physiological parameters (e.g., height, weight, blood pressure, BMI) and biochemical markers (including liver and kidney function, lipid profile, and blood glucose levels) will be collected at baseline (Week 0), Week 2, and Week 4. In addition, participants will complete appetite assessment questionnaires and other surveys to evaluate changes in appetite and gastrointestinal symptoms.
- Conditions
- Obesity
- Being tested
- WM formula liquid drink, Placebo
- Keywords
- Probiotic, Prebiotic, Glucagon-like peptide-1 (GLP-1), Blood glucose, Insulin
- Medical subject headings
- Obesity, Insulin Resistance
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
WM formula liquid drinkDietary supplement
One glass jar (50 g) of the WM formula liquid drink was administered once daily, 1 hour prior to the first meal of the day.
PlaceboDietary supplement
One glass jar (50 g) of the placebo liquid drink was administered once daily, 1 hour prior to the first meal of the day.
| Study group | Role | What they receive |
|---|---|---|
| WM formula liquid drink | Experimental | WM formula liquid drink, 50 g/glass jar Receives: Dietary Supplement: WM formula liquid drink |
| Placebo | Placebo comparator | The placebo contained the same base ingredients as the WM formula but without the active WM formula component. Receives: Dietary Supplement: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change from baseline in weight at weeks 2 and 4
Assessment of changes in weight at baseline, week 2, and week 4
Measured: Week 0, 2 and 4
Change from plasma GLP-1 concentration (pmol/L) in baseline at weeks 2 and 4
Measured: Assessment of changes in GLP-1 concentration at baseline, week 2, and week 4
Change from baseline in blood glucose at weeks 2 and 4
Assessment of blood glucose changes at weeks 0, 2, and 4
Measured: Week 0, 2 and 4
Secondary outcomes (2)
Change from plasma DPP-4 concentration (ng/mL) in baseline at weeks 2 and 4
Assessment of plasma DPP-4 concentration changes at weeks 0, 2, and 4
Measured: Week 0, 2 and 4
Change from plasma PAI-1 concentration (ng/mL) in baseline at weeks 2 and 4
Assessment of plasma PAI-1 concentration changes at weeks 0, 2, and 4
Measured: Week 0, 2 and 4
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Aug 2025
- Study start30 Aug 2025
- Primary completion30 Nov 2025
- Study completion30 Dec 2025
Why it stopped: based on an overall assessment of feasibility and strategic considerations
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for ObesityStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Care provider
- Enrolment
- 0 participants (actual)
Sponsor and investigators
- Lead sponsor
- TCI Co., Ltd.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07097974
- Sponsor's protocol ID
- 25-047-A
- Status last verified
- May 2026
- First submitted
- 30 Jul 2025
- Last updated
- 13 May 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 13 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of the Efficacy of the Composite WM Formula in Body Weight Change
- ClinicalTrials.gov ID
- NCT07097974
- Acronym / sponsor ID
- 25-047-A
- Conditions
- Obesity
- Keywords
- Probiotic, Prebiotic, Glucagon-like peptide-1 (GLP-1), Blood glucose, Insulin
- Study type
- Interventional
- Recruitment status
- WithdrawnReason stopped: based on an overall assessment of feasibility and strategic considerations
- Enrolment
- 0 participants (actual)
- Lead sponsor
- TCI Co., Ltd.Industry (pharma, biotech, devices)
- Study start
- 30 Aug 2025 (actual)
- Primary completion
- 30 Nov 2025 (actual)
- Study completion
- 30 Dec 2025 (actual)
- First posted
- 1 Aug 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to evaluate the effects of the combined formula WM Formula, used as a dietary supplement, with a focus on improvements in glycemic and lipid parameters, body composition, and gut microbiota profiles.
Detailed description
This study is a single-center, randomized, double-blind, placebo-controlled human clinical trial designed to evaluate the potential effect of the WM Formula composite supplement on body weight. Eligible participants will be adults aged 18 years or older, screened based on waist circumference or body fat percentage.
Participants will be randomly assigned to one of two groups: one receiving the combined formula WM Formula, and the other receiving a placebo. Each group will take either the WM Formula or placebo, and undergo regular assessments throughout the 4-week study period. Physiological parameters (e.g., height, weight, blood pressure, BMI) and biochemical markers (including liver and kidney function, lipid profile, and blood glucose levels) will be collected at baseline (Week 0), Week 2, and Week 4. In addition, participants will complete appetite assessment questionnaires and other surveys to evaluate changes in appetite and gastrointestinal symptoms.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, care provider)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| WM formula liquid drink | Experimental | Dietary Supplement: WM formula liquid drinkWM formula liquid drink, 50 g/glass jar |
| Placebo | Placebo comparator | Dietary Supplement: PlaceboThe placebo contained the same base ingredients as the WM formula but without the active WM formula component. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Adults aged 18 years or older who are willing to sign the informed consent form.
- Body fat percentage: ≥30% for females and ≥25% for males.
- Non-pregnant and non-lactating women who agree to use physical contraceptive methods (e.g., condoms, intrauterine devices) throughout the study period.
Key exclusion criteria (9 listed)
- Use of GLP-1 receptor agonists approved in Taiwan (e.g., liraglutide, semaglutide, dulaglutide), blood glucose-regulating medications, weight loss-related drugs or functional foods, probiotics, or gastrointestinal health-related supplements or medications within 30 days prior to the start of the study.
- History of chronic gastrointestinal disorders, seizure disorders or epilepsy, hepatic or renal diseases, malignancies, endocrine disorders, psychiatric illnesses, alcohol or drug abuse, or other major organic diseases based on medical history.
- History of gastrointestinal surgery, organ transplantation, or other major surgeries.
- History of hypoglycemia.
- Known lactose intolerance.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| WM formula liquid drinkOne glass jar (50 g) of the WM formula liquid drink was administered once daily, 1 hour prior to the first meal of the day. | Dietary supplement | WM formula liquid drink |
| PlaceboOne glass jar (50 g) of the placebo liquid drink was administered once daily, 1 hour prior to the first meal of the day. | Dietary supplement | Placebo |
Primary outcome
Change from baseline in weight at weeks 2 and 4
Time frame: Week 0, 2 and 4
Assessment of changes in weight at baseline, week 2, and week 4
Change from plasma GLP-1 concentration (pmol/L) in baseline at weeks 2 and 4
Time frame: Assessment of changes in GLP-1 concentration at baseline, week 2, and week 4
Change from baseline in blood glucose at weeks 2 and 4
Time frame: Week 0, 2 and 4
Assessment of blood glucose changes at weeks 0, 2, and 4
2 secondary outcomes
Change from plasma DPP-4 concentration (ng/mL) in baseline at weeks 2 and 4
Time frame: Week 0, 2 and 4
Change from plasma PAI-1 concentration (ng/mL) in baseline at weeks 2 and 4
Time frame: Week 0, 2 and 4
Results and safety
The study was withdrawn before enrolling participants, so there are no results.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 May 2026.
Related trials for Obesity
RecruitingObservational study
Endoscopic Sleeve Gastroplasty (ESG) Prospective Trial for Obesity (EGO-Trial)
Obesity
Active, not recruitingPhase 4
Effects of Sequential Therapy With Mexidol® (Intravenous) and Mexidol® FORTE 250 (Oral) on Functional Brain Activity Assessed by Functional Magnetic Resonance Imaging and Biochemical Parameters in Patients With Chronic Cerebral Ischemia: A Comparison of Patients With and Without Metabolic Disorders
Metabolic Abnormalities, Obesity & Overweight
Recruiting
Exercise Training and Vitamin D Metabolism
Obesity & Overweight, Vitamin D
Recruiting
Metabolic Health, Bones and Nuts During Weight Loss in Adults
Weight Loss, Bone Density
Active, not recruiting
Effect of Probiotics on Insulin Sensitivity in Overweight and Obese Pregnancy
Obesity & Overweight, Gestational Diabetes Mellitus (GDM)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing WM formula liquid drink in people with Obesity, run by TCI Co., Ltd. at 1 site in Taiwan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: withdrawn, as of the sponsor's last update on 13 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Taiwan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was withdrawn before enrolling participants, so there are no results.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change from baseline in weight at weeks 2 and 4 (time frame: Week 0, 2 and 4). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 May 2026.